Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Press release - No. 10 / 2018
Zealand Pharma will attend the Kempen Life Science Conference on April 18, 2018 in Amsterdam
Copenhagen, April 12, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will attend the Kempen Life Science Conference in Amsterdam on April 18, 2018.
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, e-mail: [email protected]
Mats Blom, Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
